Panorama

70,000 Doses of Ervebo Vaccine Against Ebola for the DR Congo

The Democratic Republic of Congo is receiving 70,000 doses of the Ervebo vaccine in the fight against Ebola, according to the WHO.

20 August 2026Tagblick Newsdesk

AI-generatedWritten by an AI system, editorially responsible — how we work

Archive photo: 70,000 Doses of Ervebo Vaccine Against Ebola for the DR Congo — Archive photoPhoto: TomPearlDesciple · Wikimedia Commons · CC0

The World Health Organization (WHO) has announced that the Democratic Republic of Congo will receive 70,000 doses of the Ervebo vaccine against Ebola. This action comes in the context of the ongoing Ebola epidemic in the country.

The doses of the vaccine are intended for limited use among at-risk individuals as well as for clinical trials. The WHO had previously confirmed the Ervebo vaccine as safe and effective against the Zaire strain of the Ebola virus.

However, the Bundibugyo variant of the virus is currently spreading in the Democratic Republic of Congo, raising questions about the vaccine's effectiveness. Ervebo has not yet been specifically tested for this variant.

To clarify the vaccine's effectiveness against the Bundibugyo variant, a clinical study will be conducted.

The provision of the vaccine is part of efforts to mitigate the health impacts of the epidemic. The WHO is supporting national health authorities in providing the necessary resources.

In recent years, the Democratic Republic of Congo has faced multiple outbreaks of Ebola, underscoring the urgency of such measures.

This item was written by an AI system on the basis of the headlines and short teasers of the independently operating newsrooms named below. We disclose this under Art. 50(4), second subparagraph, of Regulation (EU) 2024/1689 (AI Act). Before publication we check origin and verifiability — anything that appears in only one place is not published — as well as language, substance and legally sensitive content. No separate substantive review of each individual item by a natural person takes place; we therefore do not rely on the exemption in Art. 50(4), second subparagraph, of the AI Act. Editorial responsibility for this publication rests with the person named in the imprint (§ 18 Abs. 2 MStV). Please report errors to [email protected] — we will correct or remove the item. Full reports are available from the sources listed.